NEW YORK (GenomeWeb News) — Transposagen Biopharmaceuticals said today that it has expanded its license for DNA transposon technology to cover nearly all commercial applications, including as a tool for drug and biomarker discovery.

The intellectual property for the transposon technology, called piggyBac, is jointly owned by the University of Notre Dame, the University of Florida, and the US Department of Agriculture.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.